Concomitant administration of adjuvanted recombinant zoster vaccine (RZV) and tetanus and reduced diphtheria toxoid, acellular pertussis vaccine (Tdap) does not appear to affect the immunogenicity of RZV, according to findings from a recent trial published in the journal Vaccine.
The phase 3 study aimed to assess the immunogenicity, reactogenicity, and safety of RZV when the first dose is administered with Tdap in adults aged 50 years or older compared with administration of the vaccines separately. The primary outcome measures were vaccine response rate to RZV when coadministered with Tdap, as well as evidence of noninferiority in humoral response in patients who received concomitant vaccination compared with those who did not.
Results showed that when co-administered with Tdap, the vaccine response rate to RZV was 97.8%. “The noninferiority criterion was met for the humoral response to RZV and for 4 Tdap antigens, but was not met for the Tdap antigen pertactin,” the authors noted. As for safety, adverse events were found to be similar between the 2 groups.
Based on their findings, the authors concluded that patients aged 50 years and older can receive RZV and Tdap concomitantly as the “data do not suggest a clinically relevant interference.”
For more information visit sciencedirect.com.
This article originally appeared on MPR